SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450

FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging workAEON plans to submit an IND for CMAP pharmacodynamic study in the fourth quarter of 2026AEON plans to leverage its anal…

AEON

Related stories